Scagliotti GV, et al. Nintedanib + pemetrexed/cisplatin in patients with unresectable MPM: phase III results from the LUME-Meso trial. IASLC 2018, abstract PL02.09.
Lutetium-177 PSMA-617 zet belangrijke stap richting kliniek
nov 2018 | Uro-oncologie